Drug Type Small molecule drug |
Synonyms Alendronate/dextran/guanidine, ODX |
Target- |
Mechanism Iron Supplements, Osteoclasts inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC4H15NNaO8P2 |
InChIKeyHZMNHMQPEYMSTG-UHFFFAOYSA-N |
CAS Registry121268-17-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | SE | 05 Sep 2023 | |
Bone metastases | Phase 2 | EE | 01 May 2016 | |
Bone metastases | Phase 2 | FI | 01 May 2016 | |
Bone metastases | Phase 2 | LV | 01 May 2016 | |
Bone metastases | Phase 2 | SE | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | EE | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | FI | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | LV | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | SE | 01 May 2016 | |
Metastatic castration-resistant prostate cancer | Phase 2 | SE | 01 Jan 2015 |
Phase 2 | Castration-Resistant Prostatic Cancer bone alkaline phosphatase (B-ALP) | serum-aminoterminal-propeptide of Type I procollagen (S-P1NP) | serum C-terminal telopeptide | 55 | ODX 3 mg/kg | yqgejpmesp(gtmyyvbvlx) = ughxuzlaso cmovcugouc (kozakkfmsr ) | - | 01 Mar 2023 | |
ODX 6 mg/kg | yqgejpmesp(gtmyyvbvlx) = jzlgnlvqeh cmovcugouc (kozakkfmsr ) |